The Fas signaling pathway plays a central role in activating cell death. As such, it is implicated in a range of conditions and has been associated with ophthalmic diseases. ONL Therapeutics is developing therapies that target Fas signaling to address a range of retinal conditions. We spoke to Connie Chang, chief operating officer for ONL Therapeutics, about the role Fas-signaling plays in cell death, how this underlies a number of retinal diseases, and the company’s experimental therapy to inhibit Fas signaling.
Overcoming Barriers to Delivering Large Molecules to the Brain
Developing Complex Therapies to Tackle Complex Diseases
How Solving a Problem with Genetic Medicines May Solve Another with Infectious Diseases
Boosting the Power of Dendritic Cancer Vaccines
Overcoming Resistance in Cancer with Chemistry
Teaching an Old Drug a New Trick to Prevent Lyme Disease
A New Class of Cell Therapies to Target Solid Tumors
Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies
A Company Born from a Father Who Wore His Heart on His Sleeve
Using AI to Improve Burn Care
A Home for Biotech in the City that Never Sleeps
Biopharma R&D Growing Stronger
The Benefits of Having a Multitude of Cins
Making ADCs Smarter and Safer with a Simple Twist of Fate
Targeting a Natural Repair System to Restore Brain Health
Programing Cells in a Predictable and Scalable Way
Why DNA May Be the Data Storage Medium of the Future
Scouring Genetic Variation within Our Cells for Drug Targets
Correcting Gene Dysregulation to Treat Diseases
Using Technology to Regain Abilities after Spinal Cord Injury
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths